July 26, 2021
SpineThera Announces Issuance of Fourth and Fifth Patents Covering its Sustained-Release Platform Technology
MEDICAL ALLEY, MINNESOTA, UNITED STATES, July 26, 2021 /EINPresswire.com/ -- SpineThera, Inc., a privately held, clinical stage pharmaceutical company focused on the development of SX600 (a novel formulation of sustained-release dexamethasone for treatment of sciatica) announced today that the United States Patent and Trademark Office (USPTO) has recently issued U.S. Patent Number 10,925,883 entitled Pharmaceutical Compositions and Uses Thereof. The issuance of the ‘883 patent will add to the company’s growing worldwide patent portfolio and is already issued in nineteen other countries. The issued claims of this patent family are directed at composition coverage of SpineThera’s novel biodegradable, sustained-release microsphere platform technologies. The company’s lead product, SX600, is currently being evaluated in a Phase 2 clinical trial for lumbar radiculopathy (sciatica) in Australia.